Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells

Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance. As crucial rate-limiting enzymes in aerobic glycolysis and glutaminolysis, pyruvate kinase M2 type (PKM2) and kidney-type glutaminase (GLS1) are proposed to carry important implications...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Wei-Qun, Hu, Ying-Ying, Lin, Xiao-Ping, Fan, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546471/
https://www.ncbi.nlm.nih.gov/pubmed/28498807
http://dx.doi.org/10.18632/oncotarget.17396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546471/
https://www.ncbi.nlm.nih.gov/pubmed/28498807
http://dx.doi.org/10.18632/oncotarget.17396

Ejemplares similares